Elevance Health Files 8-K
Ticker: ELV · Form: 8-K · Filed: Oct 31, 2024 · CIK: 1156039
Sentiment: neutral
Topics: filing, financials, sec
TL;DR
Elevance Health filed an 8-K on Oct 31st, mostly financial docs.
AI Summary
Elevance Health, Inc. filed an 8-K on October 31, 2024, reporting an event that occurred on October 22, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Elevance Health is providing updated financial information or exhibits to the SEC, which could be relevant for investors assessing the company's financial health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 001-16751 — Commission File Number (Elevance Health's SEC filing identifier)
- 35-2145715 — IRS Employer Identification No. (Elevance Health's tax identification number)
Key Players & Entities
- Elevance Health, Inc. (company) — Registrant
- Indiana (location) — State of incorporation
- October 31, 2024 (date) — Date of Report
- October 22, 2024 (date) — Earliest event reported
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided text states the filing includes 'Financial Statements and Exhibits' but does not list the specific documents.
What was the nature of the event reported on October 22, 2024?
The filing indicates an event occurred on October 22, 2024, but the details are not specified in the provided excerpt, which focuses on the filing's administrative information.
What is Elevance Health's principal executive office address?
The principal executive offices are located at 220 Virginia Avenue, Indianapolis, IN 46204.
What is Elevance Health's telephone number?
The registrant's telephone number is (833) 401-1577.
Has Elevance Health previously operated under different names?
Yes, Elevance Health was formerly known as Anthem, Inc. (name change effective December 2, 2014), WELLPOINT, INC (name change effective January 5, 2010), and WELLPOINT INC (name change effective November 30, 2004).
Filing Stats: 1,946 words · 8 min read · ~6 pages · Grade level 10.9 · Accepted 2024-10-31 16:15:58
Key Financial Figures
- $350 million — Inc. (the "Company") closed its sale of $350 million aggregate principal amount of its 4.500
- $750 million — 500% Notes due 2026 (the "2026 Notes"), $750 million aggregate principal amount of its 4.750
- $1,200 million — 950% Notes due 2031 (the "2031 Notes"), $1,200 million aggregate principal amount of its 5.200
- $1,350 million — 200% Notes due 2035 (the "2035 Notes"), $1,350 million aggregate principal amount of its 5.700
- $800 million — % Notes due 2055 (the "2055 Notes") and $800 million aggregate principal amount of its 5.850
- $5,138.3 million — pany received proceeds of approximately $5,138.3 million from the sale of the Notes after deduct
Filing Documents
- d888716d8k.htm (8-K) — 40KB
- d888716dex11.htm (EX-1.1) — 204KB
- d888716dex42.htm (EX-4.2) — 47KB
- d888716dex43.htm (EX-4.3) — 47KB
- d888716dex44.htm (EX-4.4) — 47KB
- d888716dex45.htm (EX-4.5) — 47KB
- d888716dex46.htm (EX-4.6) — 47KB
- d888716dex47.htm (EX-4.7) — 47KB
- d888716dex51.htm (EX-5.1) — 14KB
- d888716dex52.htm (EX-5.2) — 14KB
- g888716dsp80a.jpg (GRAPHIC) — 14KB
- g888716g1030074340385.jpg (GRAPHIC) — 2KB
- 0001193125-24-248691.txt ( ) — 831KB
- elv-20241022.xsd (EX-101.SCH) — 3KB
- elv-20241022_lab.xml (EX-101.LAB) — 17KB
- elv-20241022_pre.xml (EX-101.PRE) — 11KB
- d888716d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Exhibit 1.1 Underwriting Agreement, dated as of October 22, 2024, among the Company and Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC 4.1 Indenture, dated as of November 21, 2017, among the Company and the Bank of New York Mellon Trust Company, N.A. as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 21, 2017) 4.2 Form of the 4.500% Notes due 2026 4.3 Form of the 4.750% Notes due 2030 4.4 Form of the 4.950% Notes due 2031 4.5 Form of the 5.200% Notes due 2035 4.6 Form of the 5.700% Notes due 2055 4.7 Form of the 5.850% Notes due 2064 5.1 Opinion of Hogan Lovells US LLP 5.2 Opinion of Faegre Drinker Biddle & Reath LLP 23.1 Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1) 23.2 Consent of Faegre Drinker Biddle & Reath LLP (included in the opinion filed as Exhibit 5.2) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 31, 2024 ELEVANCE HEALTH, INC. By: /s/ Kathleen S. Kiefer Name: Kathleen S. Kiefer Title: Chief Governance Officer & Corporate Secretary